According to a recent 13G filing with the US Securities and Exchange Commission, Mark Lampert‘s Biotechnology Value Fund L. P. owns 2.84 million common shares of Blueprint Medicines Corp (NASDAQ:BPMC), which amass 10.4% of the company’s outstanding stock. This is slightly more compared to 2.28 million shares Biotechnology Value Fund L. P. held in December, as reported in a previous filing.
Follow Blueprint Medicines Corp (NASDAQ:BPMC)
Follow Blueprint Medicines Corp (NASDAQ:BPMC)
Blueprint Medicines Corporation is a biopharmaceutical company that focuses on helping people suffering from genomically defined diseases driven by abnormal kinase activation. Over the past 12 months, the company’s shares have dropped by 18.51%. In March, a number of analysts updated their outlook on Blueprint Medicines Corporation’s stock, including JPMorgan Chase & Co., which lowered the price target to $37.00 from $54.00, while reporting “market outperform” rating. Blueprint Medicines Corporation is scheduled to report its financial results for the last quarter on May 10 and analysts project a loss of $0.70 per share on revenue of $3.24 million.
The number of long hedge fund positions, among those followed by Insider Monkey, in this stock has dropped by 1 recently. At the end of the third quarter of 2015, there were 14 hedge funds bullish on this stock, whereas at the end of the fourth quarter of 2015 there were 13 interested investors. At the end of December, Mark Lampert’s Biotechnology Value Fund L.P. reported the biggest position, worth around $60 million, and the second most bullish fund manager was Jacob Gottlieb of Visium Asset Management with a position worth about $26.9 million. Other hedge funds that have reported long positions in this stock are Christopher Medlock James’s Partner Fund Management, Peter Kolchinsky’s RA Capital Management, and Richard Driehaus’s Driehaus Capital.
Investors who lost interest in this stock and cut off their positions are Hal Mintz’s Sabby Capital, which dumped around $6.6 million in stock, and Israel Englander’s Millennium Management, which dropped a position worth around $0.7 million.
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Biotechnology Value Trading Fund OS | 0 | 170,320 | 0 | 170,320 | 170,320 | Less than 1% |
| BVF Partners OS Ltd | 0 | 170,320 | 0 | 170,320 | 170,320 | Less than 1% |
| BVF Partners | 0 | 2,840,251 | 0 | 2,840,251 | 2,840,251 | 10.4% |
| BVF Inc | 0 | 2,840,251 | 0 | 2,840,251 | 2,840,251 | 10.4% |
| Mark N. Lampert | 0 | 2,840,251 | 0 | 2,840,251 | 2,840,251 | 10.4% |
Page 1 of 11 – SEC Filing
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
| Blueprint Medicines Corporation |
| (Name of Issuer) |
| Common Stock, $0.001 par value |
| (Title of Class of Securities) |
| 09627Y109 |
| (CUSIP Number) |
| April 29, 2016 |
| (Date of Event Which Requires Filing of this Statement) |
| o | Rule 13d-1(b) |
| x | Rule 13d-1(c) |
| o | Rule 13d-1(d) |
_______________
